Since CX-5461 is currently in phase I/II clinical trials in Canada for breast cancer (Clinical trial identification: NCT02719977), treatment combination studies involving BRCA1/2 mutant cell lines could be informative. This evidence concerns the gene BRCA1 and breast carcinoma.